Patents by Inventor Gregory Dietsch

Gregory Dietsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20240124440
    Abstract: Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 18, 2024
    Inventors: Anjali PANDEY, Gregory DIETSCH, Bhaskar CHAUDHURI, Swapan Kumar SAMANTA, Seetharaman MANOJVEER, Mahesh THAKKAR, Athisayamani Jeyaraj DURAISWAMY, Sukesh KALVA
  • SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS
    Publication number: 20230242546
    Abstract: Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.
    Type: Application
    Filed: January 27, 2023
    Publication date: August 3, 2023
    Inventors: Anjali PANDEY, Gregory DIETSCH, Bhaskar CHAUDHURI, Seetharaman MANOJVEER, Mahesh THAKKAR, Athisayamani Jeyaraj DURAISWAMY, Sukesh KALVA
  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20230183264
    Abstract: Described herein are triazole compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.
    Type: Application
    Filed: February 3, 2023
    Publication date: June 15, 2023
    Inventors: Anjali PANDEY, Gregory DIETSCH, Bhaskar CHAUDHURI, Seetharaman MANOJVEER, Mahesh THAKKAR, Athisayamani Jeyaraj DURAISWAMY, Sukesh KALVA
  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20230174553
    Abstract: Described herein are triazole compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.
    Type: Application
    Filed: February 3, 2023
    Publication date: June 8, 2023
    Inventors: Anjali PANDEY, Gregory DIETSCH, Bhaskar CHAUDHURI, Seetharaman MANOJVEER, Mahesh THAKKAR, Athisayamani Jeyaraj DURAISWAMY, Sukesh KALVA
  • Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors
    Patent number: 11613548
    Abstract: Described herein are compounds of Formula (XVII) that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of Using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: March 28, 2023
    Assignee: SUDO BIOSCIENCES LIMITED
    Inventors: Anjali Pandey, Gregory Dietsch, Bhaskar Chaudhuri, Seetharaman Manojveer, Mahesh Thakkar, Athisayamani Jeyaraj Duraiswamy, Sukesh Kalva
  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20220281885
    Abstract: Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.
    Type: Application
    Filed: May 5, 2022
    Publication date: September 8, 2022
    Inventors: Anjali PANDEY, Gregory DIETSCH, Bhaskar CHAUDHURI, Seetharaman MANOJVEER, Mahesh THAKKAR, Athisayamani Jeyaraj DURAISWAMY, Sukesh KALVA
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 9655904
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 23, 2017
    Assignees: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
  • TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE
    Publication number: 20160331758
    Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
    Type: Application
    Filed: December 21, 2015
    Publication date: November 17, 2016
    Inventors: J. Jeffry Howbert, Muralikrishna Duvvuri, Robert Hershberg, Gregory Dietsch
  • Substituted Benzoazepines as Toll-Like Receptor Modulators
    Publication number: 20160129010
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.
    Type: Application
    Filed: August 4, 2015
    Publication date: May 12, 2016
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 9242964
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: January 26, 2016
    Assignees: VENTIRX PHARMACEUTICALS, INC., ARRAY BIOPHARMA, INC.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert M. Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • Toll-like receptor agonist formulations and their use
    Patent number: 9216192
    Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: December 22, 2015
    Assignee: VentiRx Pharmaceuticals, Inc.
    Inventors: J. Jeffry Howbert, Muralikrishna Duvvuri, Robert Hershberg, Gregory Dietsch
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 9126940
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: September 8, 2015
    Assignees: VentiRx Pharmaceuticals, Inc., Array Biopharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
  • Substituted Benzoazepines as Toll-Like Receptor Modulators
    Publication number: 20140234376
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Application
    Filed: February 14, 2014
    Publication date: August 21, 2014
    Applicants: Array BioPharma, Inc., VentiRx Pharmaceuticals, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong-Woon Yang
  • Substituted Benzoazepines as Toll-Like Receptor Modulators
    Publication number: 20140142086
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Application
    Filed: September 3, 2013
    Publication date: May 22, 2014
    Applicants: ARRAY BIOPHARMA, INC., VENTIRX PHARMACEUTICALS, INC.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert M. Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 8691809
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: April 8, 2014
    Assignees: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, Joseph P. Lyssikatos, Brad Newhouse, Hong Woon Yang
  • Substituted benzoazepines as toll-like receptor modulators
    Patent number: 8524702
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: September 3, 2013
    Assignees: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • Toll-Like Receptor Agonist Formulations and Their Use
    Publication number: 20130018042
    Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
    Type: Application
    Filed: July 16, 2012
    Publication date: January 17, 2013
    Inventors: J. Jeffry Howbert, Muralikrishna Duvvuri, Robert Hershberg, Gregory Dietsch
  • Therapeutic Use of a TLR Agonist and Combination Therapy
    Publication number: 20120219615
    Abstract: The present invention is directed generally to formulations of a TLR agonist preferably a TLR8 agonist, and its use in the treatment of various diseases, including combination therapies for treating cancer.
    Type: Application
    Filed: October 3, 2011
    Publication date: August 30, 2012
    Applicants: The Trustees of the University of Pennsylvania, VentiRx Pharmaceuticals, Inc.
    Inventors: Robert Hershberg, George Coukos, Gregory Dietsch, Andrea Facciabene, Kristi Manjarrez, Tressa D. Randall
  • Toll-like receptor agonist formulations and their use
    Patent number: 8242106
    Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: August 14, 2012
    Assignee: VentiRx Pharmaceuticals, Inc.
    Inventors: J. Jeffry Howbert, Muralikrishna Duvvuri, Robert Hershberg, Gregory Dietsch
  • SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS
    Publication number: 20110118235
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Application
    Filed: August 18, 2010
    Publication date: May 19, 2011
    Applicants: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones